<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4722">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715906</url>
  </required_header>
  <id_info>
    <org_study_id>20201530</org_study_id>
    <nct_id>NCT04715906</nct_id>
  </id_info>
  <brief_title>Project COPE (Coping Options for Parent Empowerment)</brief_title>
  <official_title>Coping Options for Parent Empowerment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Children's Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to collect information to better understand caregiver&#xD;
      responses to COVID-19 stress and to help caregivers of children with Autism Spectrum Disorder&#xD;
      (ASD) cope with these stressors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Anxiety levels as measured by GAD-7</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Parent Psychopathology levels will be reported as the change in the Generalized Anxiety Disorder 7-item (GAD-7) scores. GAD-7 is a 7-item measure assessing the presence and severity of symptoms of anxiety. The Scale has a total score ranging from 0 to 21 with the higher scores indicating greater anxiety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in depressive symptoms as measured by the PHQ</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Parent Psychopathology levels will be reported as the change in the Patient Health Questionnaire (PHQ) scores. PHQ is a 9-item measure assessing the severity of depressive symptoms. It has a total score ranging from 0 to 27 with the higher scores indicating greater depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in parenting beliefs as measured by the PSOC Scale</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Parenting Sense of Competence (PSOC) scale is a 17-item measure of parenting self-efficacy and satisfaction. It has a total score ranging from 17 to 102 with the higher scores indicating greater self-efficacy and satisfaction in the parenting role.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hope as measured by the State Hope Scale</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>State Hope Scale is a 6-item measure designed to evaluate hope in adults. It has a total score ranging from 6 to 48 with the higher scores representing higher hope levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of Intervention as measured by the Program Feedback Scale</measure>
    <time_frame>6 Weeks</time_frame>
    <description>The Program Feedback Scale has a total score ranging from 0 to 28 with the higher score indicating perceived acceptability and feasibility of the program.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Anxiety Disorders</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>UP-Caregiver Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unified Protocol (UP) Caregiver Group will receive the UP for Transdiagnostic Treatment of Emotional Disorders for Caregivers intervention via telehealth using Zoom for a minimum of 4 up to 8 sessions ideally within 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>UP-Caregiver</intervention_name>
    <description>The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.</description>
    <arm_group_label>UP-Caregiver Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be willing to consent to participate via RedCap&#xD;
&#xD;
          2. Indicate a mild or greater elevation on screening measures of anxiety and/or&#xD;
             depression&#xD;
&#xD;
          3. Not meet any exclusion criteria.&#xD;
&#xD;
          4. Lives in Florida&#xD;
&#xD;
          5. Has a child between the ages of 5-13 years who has been diagnosed with ASD&#xD;
&#xD;
          6. Speaks either English or Spanish primarily&#xD;
&#xD;
          7. Has technical capacity to participate in Zoom sessions on a mobile device or&#xD;
             preferably a computer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe mental illness (e.g., bipolar disorder, schizophrenia, an intellectual&#xD;
             disability, psychosis, alcohol use disorder, substance use disorder) or&#xD;
             hospitalization for mental health concerns or suicide attempt. Parents may receive&#xD;
             concurrent psychiatric or psychological intervention services but may be excluded if&#xD;
             the severity of current mental illness is such that outpatient, weekly group treatment&#xD;
             would be considered inappropriate.&#xD;
&#xD;
          2. Parents who report any prior arrest for child endangerment, child abuse or child&#xD;
             neglect may also be excluded.&#xD;
&#xD;
          3. Parents who have Moderate or greater risk of suicidal ideation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Ehrenreich-May, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Halliday, BS</last_name>
    <phone>305-284-2712</phone>
    <email>erh24@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Halliday</last_name>
      <email>erh24@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jill Ehrenreich-May</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Jill May Ehrenreich</investigator_full_name>
    <investigator_title>Professor, Assistant Chair for Academic Affairs and Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

